Documentation Centre

 

 

  of  Next page

Go to page: of

Screenshot Date Categories Title Author Format
Why are we shaped differently, and why does it matter? July 30, 2010 Why are we shaped differently, and why does it matter? Michael Jensen, MD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, USA Expert Opinions
Video 0:40 min.
(3 MB)
What are the current recommendations for the management of patients at risk for type 2 diabetes? July 23, 2010 What are the current recommendations for the management of patients at risk for type 2 diabetes? Edward Horton, Director of Clinical Research, Joslin Diabetes Center, Boston, MA, USA Expert Opinions
Video 2:11 min.
(11 MB)
What evidence do we have that systemic CB1 receptors are important in the pathophysiology of glycemia? July 16, 2010 What evidence do we have that systemic CB1 receptors are important in the pathophysiology of glycemia? Vincenzo Di Marzo, PhD, Istituto di Chimica Biomolecolare Pozzuoli (NA), Italy Expert Opinions
Video 0:35 min.
(3 MB)
Where should we focus our prevention efforts: in schools? July 09, 2010 Where should we focus our prevention efforts: in schools? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 0:38 min.
(3 MB)
Why do elevated HDL cholesterol concentrations not protect against cardiovascular disease? July 02, 2010 Why do elevated HDL cholesterol concentrations not protect against cardiovascular disease? Arnold von Eckardstein, MD Institute of Clinical Chemistry, University Hospital of Zurich and Center for Integrative Human Biology, University of Zurich, Zurich, Switzerland Expert Opinions
Video 1:40 min.
(8 MB)
Are we ready to measure apolipoprotein B in clinical practice? June 25, 2010 Are we ready to measure apolipoprotein B in clinical practice? Chris Packard, DSc, FRSE, Research Director, North Glasgow University Hospital, Professor of Vascular Biochemistry, University of Glasgow, Glasgow, UK Expert Opinions
Video 0:32 min.
(2 MB)
How should the consumption of healthy foods be promoted? June 18, 2010 How should the consumption of healthy foods be promoted? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 1:02 min.
(5 MB)
What are the best therapeutic options to improve HDL functions? June 11, 2010 What are the best therapeutic options to improve HDL functions? Arnold von Eckardstein, MD Institute of Clinical Chemistry, University Hospital of Zurich and Center for Integrative Human Biology, University of Zurich, Zurich, Switzerland Expert Opinions
Video 1:08 min.
(6 MB)
Could you comment on the fat storage capacity of different abdominal fat compartments? June 04, 2010 Could you comment on the fat storage capacity of different abdominal fat compartments? André Tchernof, PhD Molecular Endocrinology and Oncology Research Centre, Laval University Medical Research Centre, Québec, QC, Canada Expert Opinions
Video 0:55 min.
(4 MB)
Should nutritional supplements be recommended? May 28, 2010 Should nutritional supplements be recommended? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 0:52 min.
(4 MB)
What is the relationship between HDL and the endothelium? May 21, 2010 What is the relationship between HDL and the endothelium? Arnold von Eckardstein, MD Institute of Clinical Chemistry, University Hospital of Zurich and Center for Integrative Human Biology, University of Zurich, Zurich, Switzerland Expert Opinions
Video 1:12 min.
(6 MB)
Could you clarify the role of macrophages and the importance of angiogenesis? May 14, 2010 Could you clarify the role of macrophages and the importance of angiogenesis? Renu Virmani, MD CVPath Institute, Gaithersburg, MD, USA Expert Opinions
Video 1:59 min.
(10 MB)
With regards to the endocrine properties of adipose tissue, which fat compartment is responsible for the hypoadiponectinemia found in obese subjects? May 07, 2010 With regards to the endocrine properties of adipose tissue, which fat compartment is responsible for the hypoadiponectinemia found in obese subjects? André Tchernof, PhD Molecular Endocrinology and Oncology Research Centre, Laval University Medical Research Centre, Québec, QC, Canada Expert Opinions
Video 1:20 min.
(6 MB)
What is the status of PPAR-alpha agonists as targets for type 2 diabetes and cardiovascular disease? April 30, 2010 What is the status of PPAR-alpha agonists as targets for type 2 diabetes and cardiovascular disease? Bart Staels, PhD Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France Expert Opinions
Video 0:41 min.
(3 MB)
In the ONTARGET study, how do you explain the disconnect between the blood pressure-lowering effects of combined therapy and the lack of further reduction in CVD events? April 30, 2010 In the ONTARGET study, how do you explain the disconnect between the blood pressure-lowering effects of combined therapy and the lack of further reduction in CVD events? Luis Miguel Ruilope, MD, Professor, Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain Expert Opinions
Video 0:48 min.
(4 MB)
Why could apolipoprotein B be better than LDL cholesterol in evaluating the success of therapy? April 16, 2010 Why could apolipoprotein B be better than LDL cholesterol in evaluating the success of therapy? Chris Packard, DSc, FRSE, Research Director, North Glasgow University Hospital, Professor of Vascular Biochemistry, University of Glasgow, Glasgow, UK Expert Opinions
Video 0:44 min.
(3 MB)
What are the key features of a cardioprotective diet? April 09, 2010 What are the key features of a cardioprotective diet? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 2:05 min.
(10 MB)
Does CB1 activation affect ectopic fat accumulation? April 01, 2010 Does CB1 activation affect ectopic fat accumulation? Vincenzo Di Marzo, PhD, Istituto di Chimica Biomolecolare Pozzuoli (NA), Italy Expert Opinions
Video 1:07 min.
(5 MB)
What is the potential benefit of HDL cholesterol infusion? March 26, 2010 What is the potential benefit of HDL cholesterol infusion? H. Bryan Brewer Jr. MD, Director, Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Cardiovascular Research Institute, Washington, DC, USA Expert Opinions
Video 1:05 min.
(4 MB)
What simple lipid targets would you recommend in clinical practice? March 19, 2010 What simple lipid targets would you recommend in clinical practice? Christie Ballantyne, MD, FACC, FACP, Director, Center for Cardiovascular Disease Prevention, Chief Section of Atherosclerosis and Vascular Medicine, Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX, USA Expert Opinions
Video 0:34 min.
(2 MB)
Could you summarize the protective roles of HDL particles? Do high HDL levels confer greater protection? March 12, 2010 Could you summarize the protective roles of HDL particles? Do high HDL levels confer greater protection? Arnold von Eckardstein, MD Institute of Clinical Chemistry, University Hospital of Zurich and Center for Integrative Human Biology, University of Zurich, Zurich, Switzerland Expert Opinions
Video 1:19 min.
(5 MB)
What about the effects of HRT on quality of life? March 05, 2010 What about the effects of HRT on quality of life? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 1:20 min.
(7 MB)
What is the importance of hemorrhage in the natural progression of plaques? February 26, 2010 What is the importance of hemorrhage in the natural progression of plaques? Renu Virmani, MD CVPath Institute, Gaithersburg, MD, USA Expert Opinions
Video 0:37 min.
(3 MB)
What is the importance of adipocyte size? February 19, 2010 What is the importance of adipocyte size? André Tchernof, PhD Molecular Endocrinology and Oncology Research Centre, Laval University Medical Research Centre, Québec, QC, Canada Expert Opinions
Video 1:29 min.
(7 MB)
What are the current indications for HRT? February 12, 2010 What are the current indications for HRT? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 1:05 min.
(5 MB)
From the ONTARGET study results, does the method used to reduce blood pressure matter in terms of its impact on cardiovascular events? February 05, 2010 From the ONTARGET study results, does the method used to reduce blood pressure matter in terms of its impact on cardiovascular events? Luis Miguel Ruilope, MD, Professor, Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain Expert Opinions
Video 1:19 min.
(7 MB)
Why could apolipoprotein B be better than cholesterol in estimating cardiovascular disease risk? January 29, 2010 Why could apolipoprotein B be better than cholesterol in estimating cardiovascular disease risk? Chris Packard, DSc, FRSE , Research Director, North Glasgow University Hospital, Professor of Vascular Biochemistry, University of Glasgow, Glasgow, UK Expert Opinions
Video 0:49 min.
(4 MB)
Is the debate over regarding the harmful cardiovascular effects of HRT in post-menopausal women? January 22, 2010 Is the debate over regarding the harmful cardiovascular effects of HRT in post-menopausal women? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 1:09 min.
(6 MB)
What are the effects of CB1 activation on adipocytes? January 15, 2010 What are the effects of CB1 activation on adipocytes? Vincenzo Di Marzo, PhD, Istituto di Chimica Biomolecolare Pozzuoli (NA), Italy Expert Opinions
Video 0:49 min.
(4 MB)
Are better drugs available to raise HDL cholesterol? January 08, 2010 Are better drugs available to raise HDL cholesterol? H. Bryan Brewer, Jr., MD, Director, Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Cardiovascular Research Institute, Washington, DC, USA Expert Opinions
Video 1:23 min.
(5 MB)
In which patients should we measure apolipoprotein B? January 05, 2010 In which patients should we measure apolipoprotein B? Christie Ballantyne, MD, FACC, FACP, Director, Center for Cardiovascular Disease Prevention, Chief Section of Atherosclerosis and Vascular Medicine, Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX, USA Expert Opinions
Video 0:47 min.
(3 MB)
Could there be a link between HDL and diabetes? December 18, 2009 Could there be a link between HDL and diabetes? Arnold von Eckardstein, MD Institute of Clinical Chemistry, University Hospital of Zurich and Center for Integrative Human Biology, University of Zurich, Zurich, Switzerland Expert Opinions
Video 1:23 min.
(5 MB)
Why do we need to improve the current atherosclerosis classification? December 11, 2009 Why do we need to improve the current atherosclerosis classification? Renu Virmani, MD CVPath Institute, Gaithersburg, MD, USA Expert Opinions
Video 1:01 min.
(5 MB)
What are the differences between the subcutaneous fat compartment and the intra-abdominal fat compartment? December 04, 2009 What are the differences between the subcutaneous fat compartment and the intra-abdominal fat compartment? André Tchernof, PhD Molecular Endocrinology and Oncology Research Centre, Laval University Medical Research Centre, Québec, QC, Canada Expert Opinions
Video 1:01 min.
(5 MB)
Do you think that the relationship between adiponectin and HDL is mediated by this adipokine's effect on the liver? November 27, 2009 Do you think that the relationship between adiponectin and HDL is mediated by this adipokine's effect on the liver? Bart Staels, PhD Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France Expert Opinions
Video 0:57 min.
(5 MB)
Can we really prevent renal disease or do we only delay its complications? November 20, 2009 Can we really prevent renal disease or do we only delay its complications? Luis Miguel Ruilope, MD, Professor, Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain Expert Opinions
Video 0:54 min.
(4 MB)
Do you believe that the small, dense LDL phenotype is independently predictive of an increased risk of cardiovascular disease? November 13, 2009 Do you believe that the small, dense LDL phenotype is independently predictive of an increased risk of cardiovascular disease? Chris Packard, DSc, FRSE, Research Director, North Glasgow University Hospital, Professor of Vascular Biochemistry, University of Glasgow, Glasgow, UK Expert Opinions
Video 0:36 min.
(3 MB)
What is the status of cardiovascular prevention in post-menopausal women? November 06, 2009 What is the status of cardiovascular prevention in post-menopausal women? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 1:15 min.
(6 MB)
Where does HDL cholesterol come from? October 30, 2009 Where does HDL cholesterol come from? H. Bryan Brewer Jr. MD, Director, Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Cardiovascular Research Institute, Washington, DC, USA Expert Opinions
Video 1:04 min.
(4 MB)
Can LDL size be measured in clinical practice? October 23, 2009 Can LDL size be measured in clinical practice? Christie Ballantyne, MD, FACC, FACP, Director, Center for Cardiovascular Disease Prevention, Chief Section of Atherosclerosis and Vascular Medicine, Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX, USA Expert Opinions
Video 0:34 min.
(2 MB)
Could you comment on the heterogeneity of risk in type 2 diabetic patients? October 16, 2009 Could you comment on the heterogeneity of risk in type 2 diabetic patients? Arnold von Eckardstein, MD Institute of Clinical Chemistry, University Hospital of Zurich and Center for Integrative Human Biology, University of Zurich, Zurich, Switzerland Expert Opinions
Video 1:03 min.
(4 MB)
Why is it important to understand the process of atherosclerosis? October 09, 2009 Why is it important to understand the process of atherosclerosis? Renu Virmani, MD CVPath Institute, Gaithersburg, MD, USA Expert Opinions
Video 1:21 min.
(6 MB)
What is the biological nature of visceral fat? October 02, 2009 What is the biological nature of visceral fat? André Tchernof, PhD Molecular Endocrinology and Oncology Research Centre, Laval University Medical Research Centre, Québec, QC, Canada Expert Opinions
Video 0:38 min.
(3 MB)
Could you comment on the status of PPARγ and β/δ? September 25, 2009 Could you comment on the status of PPARγ and β/δ? Bart Staels, PhD Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France Expert Opinions
Video 1:04 min.
(6 MB)
Does obesity surgery work for everybody? September 21, 2009 Does obesity surgery work for everybody? Arya Sharma, MD, FRCPC, Professor of Medicine and Chair for Obesity Research and Management, University of Alberta, Canada Expert Opinions
Video 0:51 min.
(3 MB)
What is the link between abdominal obesity and renal disease? July 10, 2009 What is the link between abdominal obesity and renal disease? Luis Miguel Ruilope, MD, Professor, Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain Expert Opinions
Video 1:13 min.
(6 MB)
Could you comment on the role of hepatic fat accumulation as a potential contributing factor to the development of type 2 diabetes? July 03, 2009 Could you comment on the role of hepatic fat accumulation as a potential contributing factor to the development of type 2 diabetes? Chris Packard, DSc, FRSE , Research Director, North Glasgow University Hospital, Professor of Vascular Biochemistry, University of Glasgow, Glasgow, UK Expert Opinions
Video 0:40 min.
(3 MB)
What is unique about cardiovascular risk in women? June 26, 2009 What is unique about cardiovascular risk in women? Barbara V. Howard, PhD, Medstar Research Institute, Washington, DC, USA Expert Opinions
Video 0:35 min.
(3 MB)
What is the key player in cardiometabolic changes: intra-abdominal obesity or 2-AG levels? June 17, 2009 What is the key player in cardiometabolic changes: intra-abdominal obesity or 2-AG levels? Vincenzo Di Marzo, PhD, Istituto di Chimica Biomolecolare Pozzuoli (NA), Italy Expert Opinions
Video 1:10 min.
(5 MB)
In secondary prevention patients, is HDL cholesterol still important if LDL cholesterol is low? May 22, 2009 In secondary prevention patients, is HDL cholesterol still important if LDL cholesterol is low? H. Bryan Brewer, Jr., MD, Director, Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Cardiovascular Research Institute, Washington, DC, USA Expert Opinions
Video 0:35 min.
(2 MB)
Based on the JUPITER results, is hs-CRP a cause or marker of cardiovascular disease? May 15, 2009 Based on the JUPITER results, is hs-CRP a cause or marker of cardiovascular disease? Andrew M. Tonkin, MBBS, MD, MRACP, FRACP, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia Expert Opinions
Video 1:00 min.
(4 MB)
What do trials such as JUPITER and SEARCH add to the literature on the benefits of statin therapy? May 08, 2009 What do trials such as JUPITER and SEARCH add to the literature on the benefits of statin therapy? Christopher P. Cannon, MD, Associate Professor of Medicine, Harvard Medical School, Cardiovascular Division, Brigham & Women’s Hospital, Boston, MA, USA Expert Opinions
Video 0:57 min.
(4 MB)
Is there a renewed interest in the role of adipose tissue in the pathophysiology of the metabolic syndrome? April 24, 2009 Is there a renewed interest in the role of adipose tissue in the pathophysiology of the metabolic syndrome? Ulf Smith, MD, PhD, Professor of Internal Medicine, The Lundberg Laboratory for Diabetes Research, Center of Excellence for Cardiovascular and Metabolic Research, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden Expert Opinions
Video 0:50 min.
(2 MB)
Is there a need for a global cardiometabolic risk algorithm? April 17, 2009 Is there a need for a global cardiometabolic risk algorithm? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 0:41 min.
(2 MB)
The endocrine function of adipose tissue has been an exciting development. However, there is a plethora of 'adipokines'. Which ones are getting closer to prime time and why? April 09, 2009 The endocrine function of adipose tissue has been an exciting development. However, there is a plethora of 'adipokines'. Which ones are getting closer to prime time and why? Ulf Smith, MD, PhD, Professor of Internal Medicine, The Lundberg Laboratory for Diabetes Research, Center of Excellence for Cardiovascular and Metabolic Research, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden Expert Opinions
Video 1:09 min.
(3 MB)
What is the rationale for combination therapy in the treatment of dyslipidemia? April 03, 2009 What is the rationale for combination therapy in the treatment of dyslipidemia? H. Bryan Brewer, Jr., MD, Director, Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Cardiovascular Research Institute, Washington, DC, USA Expert Opinions
Video 1:02 min.
(2 MB)
How do you see the contribution of hypoadiponectinemic state of visceral obesity in the modulation of global cardiometabolic risk? March 27, 2009 How do you see the contribution of hypoadiponectinemic state of visceral obesity in the modulation of global cardiometabolic risk? Arya Sharma, MD, FRCPC, Professor of Medicine and Chair for Obesity Research and Management, University of Alberta, Edmonton, Canada Expert Opinions
Video 0:49 min.
(1 MB)
Could you comment on how the presence/absence of the metabolic syndrome affects the management of patients with hypertension? March 20, 2009 Could you comment on how the presence/absence of the metabolic syndrome affects the management of patients with hypertension? Luis Miguel Ruilope, MD, Professor, Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain Expert Opinions
Video 2:04 min.
(7 MB)
How do you see the mobilization of fat cells? March 13, 2009 How do you see the mobilization of fat cells? Max Lafontan, PhD, Research Director, INSERM, Laboratoire de Recherche sur les Obésités, U858, Institut de Médecine Moléculaire de Rangueil, Toulouse, France Expert Opinions
Video 2:08 min.
(7 MB)
Is it possible to implement a lifestyle modification program in clinical practice? March 06, 2009 Is it possible to implement a lifestyle modification program in clinical practice? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 2:22 min.
(7 MB)
What is the mechanism for the low HDL cholesterol levels in patients with abdominal obesity and the metabolic syndrome? February 27, 2009 What is the mechanism for the low HDL cholesterol levels in patients with abdominal obesity and the metabolic syndrome? Philip J. Barter, MD, MBBS, FRACP, PhD, Professor and Director, the Heart Research Institute, Sydney, Australia Expert Opinions
Video 1:35 min.
(3 MB)
What is the key message from the INTERHEART study? February 20, 2009 What is the key message from the INTERHEART study? Luc Van Gaal, MD, PhD, Professor of Medicine, Antwerp University Hospital, Faculty of Medicine, Department of Diabetology, Metabolism & Clinical Nutrition, Antwerp, Belgium Expert Opinions
Video 1:01 min.
(3 MB)
Your own work has focused on the cytokine IL-6. How important is adipose tissue in the production/effect of that cytokine in abdominal obesity? Is this cytokine atherogenic and diabetogenic? February 13, 2009 Your own work has focused on the cytokine IL-6. How important is adipose tissue in the production/effect of that cytokine in abdominal obesity? Is this cytokine atherogenic and diabetogenic? Ulf Smith, MD, PhD, Professor of Internal Medicine, The Lundberg Laboratory for Diabetes Research, Center of Excellence for Cardiovascular and Metabolic Research, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden Expert Opinions
Video 1:15 min.
(3 MB)
How exciting for you is the discovery of adiponectin? February 06, 2009 How exciting for you is the discovery of adiponectin? Arya Sharma, MD, FRCPC, Professor of Medicine and Chair for Obesity Research and Management, University of Alberta, Edmonton, Canada Expert Opinions
Video 0:57 min.
(2 MB)
How do you see global CVD risk assessment in the future? January 30, 2009 How do you see global CVD risk assessment in the future? Luis Miguel Ruilope, MD, Professor, Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain Expert Opinions
Video 2:18 min.
(7 MB)
What are the next steps in the biology of adipose tissue? January 23, 2009 What are the next steps in the biology of adipose tissue? Max Lafontan, PhD, Research Director, INSERM, Laboratoire de Recherche sur les Obésités, U858, Institut de Médecine Moléculaire de Rangueil, Toulouse, France Expert Opinions
Video 1:19 min.
(4 MB)
Can we measure waist circumference in clinical practice? Does it make a difference? January 16, 2009 Can we measure waist circumference in clinical practice? Does it make a difference? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 1:36 min.
(5 MB)
How much progress has been made in the development of screening tools to identify individuals with features of the metabolic syndrome in the Asian population? January 09, 2009 How much progress has been made in the development of screening tools to identify individuals with features of the metabolic syndrome in the Asian population? Juliana Chan, MD, FRCP, Professor of Medicine and Therapeutics, Director, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong SAR, China Expert Opinions
Video 1:14 min.
(3 MB)
What is the role of low HDL cholesterol in the elevated CHD risk of metabolic syndrome patients? January 05, 2009 What is the role of low HDL cholesterol in the elevated CHD risk of metabolic syndrome patients? Philip J. Barter, MD, MBBS, FRACP, PhD, Professor and Director, the Heart Research Institute, Sydney, Australia Expert Opinions
Video 0:58 min.
(2 MB)
Could you comment on waist circumference measurement variability? December 19, 2008 Could you comment on waist circumference measurement variability? Luc Van Gaal, MD, PhD, Professor of Medicine, Antwerp University Hospital, Faculty of Medicine, Department of Diabetology, Metabolism & Clinical Nutrition, Antwerp, Belgium Expert Opinions
Video 0:46 min.
(2 MB)
Do you see a primary defect in the adipose tissue of individuals with a strong family history of diabetes or should we look elsewhere? December 12, 2008 Do you see a primary defect in the adipose tissue of individuals with a strong family history of diabetes or should we look elsewhere? Ulf Smith, MD, PhD, Professor of Internal Medicine, The Lundberg Laboratory for Diabetes Research, Center of Excellence for Cardiovascular and Metabolic Research, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden Expert Opinions
Video 1:05 min.
(3 MB)
Could you comment on the role played by expanded visceral adipose tissue as an endocrine organ? December 05, 2008 Could you comment on the role played by expanded visceral adipose tissue as an endocrine organ? Arya Sharma, MD, FRCPC, Professor of Medicine and Chair for Obesity Research and Management, University of Alberta, Edmonton, Canada Expert Opinions
Video 0:49 min.
(2 MB)
Could you comment on the fact that about 50% of hypertensive patients have insulin resistance whereas the other half do not show evidence of insulin resistance? November 28, 2008 Could you comment on the fact that about 50% of hypertensive patients have insulin resistance whereas the other half do not show evidence of insulin resistance? Luis Miguel Ruilope, MD, Professor, Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain Expert Opinions
Video 1:01 min.
(2 MB)
What is the right amount of fat? November 21, 2008 What is the right amount of fat? Stephen O'Rahilly, MD, FRCP, FRS, Head of Department and Professor of Clinical Biochemistry and Medicine, University of Cambridge, Cambridge, UK Expert Opinions
Video 1:14 min.
(4 MB)
Could you comment on the biology of adipose tissue? November 14, 2008 Could you comment on the biology of adipose tissue? Max Lafontan, PhD, Research Director, INSERM, Laboratoire de Recherche sur les Obésités, U858, Institut de Médecine Moléculaire de Rangueil, Toulouse, France Expert Opinions
Video 1:30 min.
(5 MB)
Considering the strengths and limitations of carotid IMT measurement, what have we learned from it regarding CVD factors: confirmatory findings or new factors/markers? November 07, 2008 Considering the strengths and limitations of carotid IMT measurement, what have we learned from it regarding CVD factors: confirmatory findings or new factors/markers? John J. Kastelein, MD, Professor of Medicine and Chairman of the Department of Vascular Medicine at the University of Amsterdam, Amsterdam, The Netherlands Expert Opinions
Video 0:53 min.
(2 MB)
What can the family doctor do to assess global cardiometabolic risk? October 31, 2008 What can the family doctor do to assess global cardiometabolic risk? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 1:40 min.
(5 MB)
Is there evidence for population differences in the relationship of waist circumference to visceral fat deposition? October 24, 2008 Is there evidence for population differences in the relationship of waist circumference to visceral fat deposition? Juliana Chan, MD, FRCP, Professor of Medicine and Therapeutics, Director, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong SAR, China Expert Opinions
Video 0:48 min.
(2 MB)
Visceral obesity has been shown to be the atherogenic/diabetogenic form of obesity. Why are we still talking about weight and BMI? October 17, 2008 Visceral obesity has been shown to be the atherogenic/diabetogenic form of obesity. Why are we still talking about weight and BMI? John D. Brunzell, MD, Professor of Medicine-Emeritus, active, University of Washington, Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, Seattle, WA, USA Expert Opinions
Video 1:17 min.
(2 MB)
What are the approaches to increase HDL cholesterol? October 10, 2008 What are the approaches to increase HDL cholesterol? H. Bryan Brewer, Jr., MD, Director, Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Cardiovascular Research Institute, Washington, DC, USA Expert Opinions
Video 2:36 min.
(6 MB)
Why is it important to raise HDL cholesterol levels? October 03, 2008 Why is it important to raise HDL cholesterol levels? Philip J. Barter, MD, MBBS, FRACP, PhD, Professor and Director, the Heart Research Institute, Sydney, Australia Expert Opinions
Video 0:46 min.
(1 MB)
Could you comment on the importance of measuring waist circumference beyond BMI to properly identify high-risk patients? September 26, 2008 Could you comment on the importance of measuring waist circumference beyond BMI to properly identify high-risk patients? Luc Van Gaal, MD, PhD, Professor of Medicine, Antwerp University Hospital, Faculty of Medicine, Department of Diabetology, Metabolism & Clinical Nutrition, Antwerp, Belgium Expert Opinions
Video 1:08 min.
(3 MB)
Do you think that omental fat per se plays a role in the pathophysiology of the metabolic syndrome or is it just a marker of "dysfunctional" adipose tissue? September 19, 2008 Do you think that omental fat per se plays a role in the pathophysiology of the metabolic syndrome or is it just a marker of "dysfunctional" adipose tissue? Ulf Smith, MD, PhD, Professor of Internal Medicine, The Lundberg Laboratory for Diabetes Research, Center of Excellence for Cardiovascular and Metabolic Research, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden Expert Opinions
Video 0:37 min.
(1 MB)
What is the role of adipose tissue function in the overall "dysmetabolic" profile found in abdominally obese type 2 diabetic patients? September 15, 2008 What is the role of adipose tissue function in the overall "dysmetabolic" profile found in abdominally obese type 2 diabetic patients? Ulf Smith, MD, PhD, Professor of Internal Medicine, The Lundberg Laboratory for Diabetes Research, Center of Excellence for Cardiovascular and Metabolic Research, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden Expert Opinions
Video 1:14 min.
(3 MB)
How can we assess visceral obesity in clinical practice? September 05, 2008 How can we assess visceral obesity in clinical practice? John D. Brunzell, MD, Professor of Medicine-Emeritus, active, University of Washington, Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, Seattle, WA, USA Expert Opinions
Video 0:53 min.
(3 MB)
What are the anti-inflammatory properties of HDL? August 29, 2008 What are the anti-inflammatory properties of HDL? H. Bryan Brewer, Jr., MD, Director, Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Cardiovascular Research Institute, Washington, DC, USA Expert Opinions
Video 1:16 min.
(2 MB)
Is there a role for new markers in clinical practice? September 07, 2007 Is there a role for new markers in clinical practice? Christie Ballantyne, MD, FACC, FACP, Director, Center for Cardiovascular Disease Prevention, Chief Section of Atherosclerosis and Vascular Medicine, Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX, USA Expert Opinions
Video 0:37 min.
(2 MB)
Does the thrombosis/fibrinolysis component of the metabolic syndrome receive enough consideration in clinical practice? September 07, 2007 Does the thrombosis/fibrinolysis component of the metabolic syndrome receive enough consideration in clinical practice? Luc Van Gaal, MD, PhD, Professor of Medicine, Antwerp University Hospital, Faculty of Medicine, Department of Diabetology, Metabolism & Clinical Nutrition, Antwerp, Belgium Expert Opinions
Video 1:22 min.
(5 MB)
Is the cardiometabolic risk profile of type 2 diabetic patients significantly worse than it was 10 years ago? September 07, 2007 Is the cardiometabolic risk profile of type 2 diabetic patients significantly worse than it was 10 years ago? Luc Van Gaal, MD, PhD, Professor of Medicine, Antwerp University Hospital, Faculty of Medicine, Department of Diabetology, Metabolism & Clinical Nutrition, Antwerp, Belgium Expert Opinions
Video 1:08 min.
(5 MB)
Could you discuss managing hypertension among patients with visceral obesity and the metabolic syndrome? September 07, 2007 Could you discuss managing hypertension among patients with visceral obesity and the metabolic syndrome? Arya Sharma, MD, FRCPC, Professor of Medicine and Chair for Obesity Research and Management, University of Alberta, Edmonton, Canada Expert Opinions
Video 1:02 min.
(3 MB)
What is the link between visceral obesity and hypertension? Are factors other than hyperinsulinemia involved? September 07, 2007 What is the link between visceral obesity and hypertension? Are factors other than hyperinsulinemia involved? Arya Sharma, MD, FRCPC, Professor of Medicine and Chair for Obesity Research and Management, University of Alberta, Edmonton, Canada Expert Opinions
Video 1:00 min.
(4 MB)
The metabolic syndrome of visceral obesity: is it overconsumption of calories or lack of physical activity? September 07, 2007 The metabolic syndrome of visceral obesity: is it overconsumption of calories or lack of physical activity? Robert Ross, PhD, Professor, School of Kinesiology and Health Studies, Department of Medicine, Division of Endocrinology and Metabolism, Queen's University, Kingston, ON, Canada Expert Opinions
Video 2:13 min.
(7 MB)
Could you comment on the respective importance of visceral adiposity vs. liver fat with regard to elevated cardiometabolic risk? September 07, 2007 Could you comment on the respective importance of visceral adiposity vs. liver fat with regard to elevated cardiometabolic risk? Robert Ross, PhD, Professor, School of Kinesiology and Health Studies, Department of Medicine, Division of Endocrinology and Metabolism, Queen's University, Kingston, ON, Canada Expert Opinions
Video 1:26 min.
(5 MB)
Does measuring waist circumference add to information provided by BMI in clinical practice? September 07, 2007 Does measuring waist circumference add to information provided by BMI in clinical practice? Robert Ross, PhD, Professor, School of Kinesiology and Health Studies, Department of Medicine, Division of Endocrinology and Metabolism, Queen's University, Kingston, ON, Canada Expert Opinions
Video 1:04 min.
(3 MB)
What is the usefulness of apo B in clinical practice? September 07, 2007 What is the usefulness of apo B in clinical practice? Göran Walldius, MD, PhD, Professor, King Gustaf V Research Institute, Karolinska Institute, Stockholm, Medical Director, Cardiovascular Unit, Marketing at AstraZeneca AB, Södertälje, Sweden Expert Opinions
Video 0:36 min.
(2 MB)
Which measures should be prioritized when assessing and managing cardiometabolic risk in Asia? September 07, 2007 Which measures should be prioritized when assessing and managing cardiometabolic risk in Asia? Juliana Chan, MD, FRCP, Professor of Medicine and Therapeutics, Director, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong SAR, China Expert Opinions
Video 1:47 min.
(6 MB)
What is the importance of HDL? September 07, 2007 What is the importance of HDL? H. Bryan Brewer, Jr., MD, Director, Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Cardiovascular Research Institute, Washington, DC, USA Expert Opinions
Video 1:09 min.
(4 MB)
Can a consensus be reached regarding the key elements of the metabolic syndrome? September 07, 2007 Can a consensus be reached regarding the key elements of the metabolic syndrome? Philip J. Barter, MD, MBBS, FRACP, PhD, Professor and Director, the Heart Research Institute, Sydney, Australia Expert Opinions
Video 1:09 min.
(4 MB)
What are the anti-inflammatory properties of HDL? September 07, 2007 What are the anti-inflammatory properties of HDL? Philip J. Barter, MD, MBBS, FRACP, PhD, Professor and Director, the Heart Research Institute, Sydney, Australia Expert Opinions
Video 1:17 min.
(4 MB)
Is abdominal obesity important in CVD risk assessment and management in type 2 diabetes? September 06, 2007 Is abdominal obesity important in CVD risk assessment and management in type 2 diabetes? Marja-Riitta Taskinen, MD, PhD, Professor of Medicine, University of Helsinki, Department of Medicine, Biomedicum, Helsinki, Finland Expert Opinions
Video 1:34 min.
(5 MB)
Which features of type 2 diabetes dyslipidemia contribute to CVD risk and which features of the dyslipidemic state should we target for optimal management of CVD risk in type 2 diabetes? September 06, 2007 Which features of type 2 diabetes dyslipidemia contribute to CVD risk and which features of the dyslipidemic state should we target for optimal management of CVD risk in type 2 diabetes? Marja-Riitta Taskinen, MD, PhD, Professor of Medicine, University of Helsinki, Department of Medicine, Biomedicum, Helsinki, Finland Expert Opinions
Video 1:56 min.
(6 MB)
Could you comment on the mechanism responsible for type 2 diabetes hypertriglyceridemia? September 06, 2007 Could you comment on the mechanism responsible for type 2 diabetes hypertriglyceridemia? Marja-Riitta Taskinen, MD, PhD, Professor of Medicine, University of Helsinki, Department of Medicine, Biomedicum, Helsinki, Finland Expert Opinions
Video 1:31 min.
(5 MB)
What is the typical dyslipidemia of type 2 diabetes? September 06, 2007 What is the typical dyslipidemia of type 2 diabetes? Marja-Riitta Taskinen, MD, PhD, Professor of Medicine, University of Helsinki, Department of Medicine, Biomedicum, Helsinki, Finland Expert Opinions
Video 1:05 min.
(3 MB)
Could you comment on the heterogeneity of CVD risk in type 2 diabetes patients? September 06, 2007 Could you comment on the heterogeneity of CVD risk in type 2 diabetes patients? Marja-Riitta Taskinen, MD, PhD, Professor of Medicine, University of Helsinki, Department of Medicine, Biomedicum, Helsinki, Finland Expert Opinions
Video 1:05 min.
(3 MB)
What is the link between visceral adiposity, insulin resistance, and hypertension? September 06, 2007 What is the link between visceral adiposity, insulin resistance, and hypertension? Luis Miguel Ruilope, MD, Professor, Internal Medicine, Complutense University, Head of the Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain Expert Opinions
Video 0:50 min.
(3 MB)
Could you comment on the importance of having a normal adipose tissue mass? September 01, 2007 Could you comment on the importance of having a normal adipose tissue mass? Max Lafontan, PhD, Research Director, INSERM, Laboratoire de Recherche sur les Obésités, U858, Institut de Médecine Moléculaire de Rangueil, Toulouse, France Expert Opinions
Video 1:11 min.
(4 MB)
Is visceral obesity a marker of ectopic fat distribution? September 01, 2007 Is visceral obesity a marker of ectopic fat distribution? Stephen O'Rahilly, MD, FRCP, FRS, Head of Department and Professor of Clinical Biochemistry and Medicine, University of Cambridge, Cambridge, UK Expert Opinions
Video 0:56 min.
(3 MB)
Should we redefine what constitutes obesity? Is it excess adipose tissue mass or rather dysfunctional adipose tissue? September 01, 2007 Should we redefine what constitutes obesity? Is it excess adipose tissue mass or rather dysfunctional adipose tissue? Stephen O'Rahilly, MD, FRCP, FRS, Head of Department and Professor of Clinical Biochemistry and Medicine, University of Cambridge, Cambridge, UK Expert Opinions
Video 1:11 min.
(4 MB)
What are the clinical implications of the dysmetabolic profile of lipodystrophic patients? How does this affect the key causes of the metabolic syndrome? September 01, 2007 What are the clinical implications of the dysmetabolic profile of lipodystrophic patients? How does this affect the key causes of the metabolic syndrome? Stephen O'Rahilly, MD, FRCP, FRS, Head of Department and Professor of Clinical Biochemistry and Medicine, University of Cambridge, Cambridge, UK Expert Opinions
Video 1:26 min.
(5 MB)
What is the relationship between an inflammatory state and  atherosclerotic plaques? September 01, 2007 What is the relationship between an inflammatory state and atherosclerotic plaques? Peter Libby, MD, Mallinckrodt Professor of Medicine, Harvard Medical School and Chief, Cardiovascular Medicine, Brigham & Women's Hospital, Boston, MA, USA Expert Opinions
Video 1:31 min.
(5 MB)
Do you believe it is important to measure CRP? September 01, 2007 Do you believe it is important to measure CRP? Peter Libby, MD, Mallinckrodt Professor of Medicine, Harvard Medical School and Chief, Cardiovascular Medicine, Brigham & Women's Hospital, Boston, MA, USA Expert Opinions
Video 2:18 min.
(8 MB)
What is the importance of adipose tissue as an endocrine organ? September 01, 2007 What is the importance of adipose tissue as an endocrine organ? Max Lafontan, PhD, Research Director, INSERM, Laboratoire de Recherche sur les Obésités, U858, Institut de Médecine Moléculaire de Rangueil, Toulouse, France Expert Opinions
Video 2:08 min.
(7 MB)
Could the endocannabinoid system be a major player in the etiology of liver steatosis? September 01, 2007 Could the endocannabinoid system be a major player in the etiology of liver steatosis? George Kunos, MD, PhD, Research Scientist, Bethesda, MD, USA Expert Opinions
Video 2:21 min.
(8 MB)
Is there evidence for a direct role of endocannabinoids on cardiovascular disease? September 01, 2007 Is there evidence for a direct role of endocannabinoids on cardiovascular disease? George Kunos, MD, PhD, Research Scientist, Bethesda, MD, USA Expert Opinions
Video 2:49 min.
(10 MB)
How feasible do you think it will be to incorporate imaging technologies in the assessment of patients' global CVD risk? September 01, 2007 How feasible do you think it will be to incorporate imaging technologies in the assessment of patients' global CVD risk? John J. Kastelein, MD, Professor of Medicine and Chairman of the Department of Vascular Medicine at the University of Amsterdam, Amsterdam, The Netherlands Expert Opinions
Video 0:41 min.
(2 MB)
Are visceral obesity, liver fat infiltration, and dysfunctional adipose tissue related? September 01, 2007 Are visceral obesity, liver fat infiltration, and dysfunctional adipose tissue related? Scott M. Grundy Expert Opinions
Video 0:46 min.
(2 MB)
Which factors/markers do you think will emerge as key predictors of global CMR beyond the Framingham risk score? September 01, 2007 Which factors/markers do you think will emerge as key predictors of global CMR beyond the Framingham risk score? Scott M. Grundy Expert Opinions
Video 0:32 min.
(1 MB)
What role does exercise/physical activity play in the management of abdominal obesity? September 01, 2007 What role does exercise/physical activity play in the management of abdominal obesity? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 1:46 min.
(6 MB)
What role does lack of physical activity play in the etiology of the metabolic syndrome? September 01, 2007 What role does lack of physical activity play in the etiology of the metabolic syndrome? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 0:30 min.
(1 MB)
What is the relationship between physical activity and the metabolic syndrome? September 01, 2007 What is the relationship between physical activity and the metabolic syndrome? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 1:04 min.
(4 MB)
What is cardiometabolic risk, and is it a new term to replace the metabolic syndrome? September 01, 2007 What is cardiometabolic risk, and is it a new term to replace the metabolic syndrome? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 1:16 min.
(5 MB)
Does the metabolic syndrome exist? September 01, 2007 Does the metabolic syndrome exist? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 1:24 min.
(5 MB)
Is there a distinction to be made between the insulin resistance syndrome and the metabolic syndrome? Are they the same thing? September 01, 2007 Is there a distinction to be made between the insulin resistance syndrome and the metabolic syndrome? Are they the same thing? Jean-Pierre Després, PhD, FAHA, Scientific Director, International Chair on Cardiometabolic Risk, Professor, Division of Kinesiology, Université Laval, Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada Expert Opinions
Video 1:41 min.
(7 MB)
Do you believe that the metabolic syndrome is as much of an issue in Asia as it is in North America? September 01, 2007 Do you believe that the metabolic syndrome is as much of an issue in Asia as it is in North America? Juliana Chan, MD, FRCP, Professor of Medicine and Therapeutics, Director, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong SAR, China Expert Opinions
Video 0:58 min.
(3 MB)
There is evidence that BMI values associated with increased  type 2 diabetes and CVD risk are lower in Asia than in the rest of the world. Which factors explain this discrepancy? What about the role of visceral adiposity? September 01, 2007 There is evidence that BMI values associated with increased type 2 diabetes and CVD risk are lower in Asia than in the rest of the world. Which factors explain this discrepancy? What about the role of visceral adiposity? Juliana Chan, MD, FRCP, Professor of Medicine and Therapeutics, Director, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong SAR, China Expert Opinions
Video 0:27 min.
(1 MB)
Could you comment on the epidemic proportions reached by type 2 diabetes in Asia? Is abdominal obesity a factor? August 31, 2007 Could you comment on the epidemic proportions reached by type 2 diabetes in Asia? Is abdominal obesity a factor? Juliana Chan, MD, FRCP, Professor of Medicine and Therapeutics, Director, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong SAR, China Expert Opinions
Video 0:30 min.
(1 MB)
Which mechanisms are responsible for the link between visceral obesity and atherogenic dyslipidemia? August 31, 2007 Which mechanisms are responsible for the link between visceral obesity and atherogenic dyslipidemia? John D. Brunzell, MD, Professor of Medicine-Emeritus, active, University of Washington, Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, Seattle, WA, USA Expert Opinions
Video 0:57 min.
(3 MB)
What is the atherogenic dyslipidemia of visceral obesity? August 31, 2007 What is the atherogenic dyslipidemia of visceral obesity? John D. Brunzell, MD, Professor of Medicine-Emeritus, active, University of Washington, Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, Seattle, WA, USA Expert Opinions
Video 1:02 min.
(3 MB)
What is the status of the debate on the metabolic syndrome? August 31, 2007 What is the status of the debate on the metabolic syndrome? Philip J. Barter, MD, MBBS, FRACP, PhD, Professor and Director, the Heart Research Institute, Sydney, Australia Expert Opinions
Video 0:52 min.
(3 MB)
What are the consequences of the obesity epidemic? August 31, 2007 What are the consequences of the obesity epidemic? Christie Ballantyne, MD, FACC, FACP, Director, Center for Cardiovascular Disease Prevention, Chief Section of Atherosclerosis and Vascular Medicine, Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX, USA Expert Opinions
Video 0:44 min.
(2 MB)

  of  Next page

Go to page: of